TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL…
Read more
News & Views
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL…
Read more
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,…
Read more
Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German…
Read more
Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live…
Read more
Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…
Read more
Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR…
Read more
Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced…
Read more
Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial…
Read more
News,
Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa…
Read more
Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development…
Read more